Limits...
Biological reconstruction following the resection of malignant bone tumors of the pelvis.

Traub F, Andreou D, Niethard M, Tiedke C, Werner M, Tunn PU - Sarcoma (2013)

Bottom Line: Two- and five-year disease-specific survival rates of all patients were 86.1% and 57.7%, respectively.The mean functional MSTS score was 16.5 (~55%) for all patients.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany.

ABSTRACT
Background. Surgical treatment of malignant pelvic bone tumors can be very challenging. The objective of this retrospective study was to evaluate the oncological as well as the clinical and functional outcome after limb salvage surgery and biological reconstruction. Methods. The files of 27 patients with malignant pelvic bone tumors, who underwent surgical resection at our department between 2000 and 2011, were retrospectively analyzed (9 Ewing's sarcoma, 8 chondrosarcoma, 4 osteosarcoma, 1 synovial sarcoma, 1 malignant fibrous histiocytoma, and 4 carcinoma metastases). Results. After internal hemipelvectomy reconstruction was performed by hip transposition (n = 16), using autologous nonvascularised fibular graft (n = 5) or autologous iliac crest bone graft (n = 2). In one patient a proximal femor prothetis and in three patients a total hip prosthesis was implanted at the time of resection. The median follow-up was 33 months. Two- and five-year disease-specific survival rates of all patients were 86.1% and 57.7%, respectively. The mean functional MSTS score was 16.5 (~55%) for all patients. Conclusion. On the basis of the oncological as well as the clinical and functional outcome, biological reconstruction after internal hemipelvectomy seems to be a reliable technique for treating patients with a malignant pelvic bone tumor.

No MeSH data available.


Related in: MedlinePlus

(a) CT reconstruction of the pelvis of a 15-year-old girl with a chondrosarcoma of the left os pubis and os ischii. (b) Anteroposterior radiograph after P3 resection.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3649758&req=5

fig4: (a) CT reconstruction of the pelvis of a 15-year-old girl with a chondrosarcoma of the left os pubis and os ischii. (b) Anteroposterior radiograph after P3 resection.

Mentions: The mean functional MSTS score was 16.5 (~55%) for all patients. Three patients were able to walk without any support (Figure 4), two had a transposition after P2-3 resection, and the other patient had a P1 resection and was reconstructed with an autologous iliac crest bone graft. All the other patients need at least one cane for longer distances. The MSTS score in the subgroups after resection and biological reconstruction was after P1 resection 16,9 (10–26), after P1-2 resection 16 (14–18) and after P1-3 resp. P2-3 resection 17,4 (9–30). The MSTS score in the patient with the P1+4 resection was 18, and in the patient after P2-4 resection was 20.


Biological reconstruction following the resection of malignant bone tumors of the pelvis.

Traub F, Andreou D, Niethard M, Tiedke C, Werner M, Tunn PU - Sarcoma (2013)

(a) CT reconstruction of the pelvis of a 15-year-old girl with a chondrosarcoma of the left os pubis and os ischii. (b) Anteroposterior radiograph after P3 resection.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3649758&req=5

fig4: (a) CT reconstruction of the pelvis of a 15-year-old girl with a chondrosarcoma of the left os pubis and os ischii. (b) Anteroposterior radiograph after P3 resection.
Mentions: The mean functional MSTS score was 16.5 (~55%) for all patients. Three patients were able to walk without any support (Figure 4), two had a transposition after P2-3 resection, and the other patient had a P1 resection and was reconstructed with an autologous iliac crest bone graft. All the other patients need at least one cane for longer distances. The MSTS score in the subgroups after resection and biological reconstruction was after P1 resection 16,9 (10–26), after P1-2 resection 16 (14–18) and after P1-3 resp. P2-3 resection 17,4 (9–30). The MSTS score in the patient with the P1+4 resection was 18, and in the patient after P2-4 resection was 20.

Bottom Line: Two- and five-year disease-specific survival rates of all patients were 86.1% and 57.7%, respectively.The mean functional MSTS score was 16.5 (~55%) for all patients.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany.

ABSTRACT
Background. Surgical treatment of malignant pelvic bone tumors can be very challenging. The objective of this retrospective study was to evaluate the oncological as well as the clinical and functional outcome after limb salvage surgery and biological reconstruction. Methods. The files of 27 patients with malignant pelvic bone tumors, who underwent surgical resection at our department between 2000 and 2011, were retrospectively analyzed (9 Ewing's sarcoma, 8 chondrosarcoma, 4 osteosarcoma, 1 synovial sarcoma, 1 malignant fibrous histiocytoma, and 4 carcinoma metastases). Results. After internal hemipelvectomy reconstruction was performed by hip transposition (n = 16), using autologous nonvascularised fibular graft (n = 5) or autologous iliac crest bone graft (n = 2). In one patient a proximal femor prothetis and in three patients a total hip prosthesis was implanted at the time of resection. The median follow-up was 33 months. Two- and five-year disease-specific survival rates of all patients were 86.1% and 57.7%, respectively. The mean functional MSTS score was 16.5 (~55%) for all patients. Conclusion. On the basis of the oncological as well as the clinical and functional outcome, biological reconstruction after internal hemipelvectomy seems to be a reliable technique for treating patients with a malignant pelvic bone tumor.

No MeSH data available.


Related in: MedlinePlus